Catalent, Inc. (NYSE:CTLT) Receives $52.46 Average Target Price from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have earned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $52.46.

CTLT has been the subject of several analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Barclays upped their target price on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. UBS Group restated a “neutral” rating and issued a $63.50 target price (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. StockNews.com assumed coverage on shares of Catalent in a research note on Friday, April 19th. They issued a “sell” rating for the company. Finally, Stephens reiterated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th.

Institutional Trading of Catalent

A number of institutional investors and hedge funds have recently modified their holdings of the business. IFM Investors Pty Ltd raised its holdings in shares of Catalent by 10.5% during the first quarter. IFM Investors Pty Ltd now owns 35,543 shares of the company’s stock worth $2,006,000 after purchasing an additional 3,372 shares during the period. Norden Group LLC acquired a new stake in shares of Catalent in the 1st quarter worth about $1,222,000. Sound Income Strategies LLC increased its holdings in shares of Catalent by 4,466.7% in the 1st quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock worth $77,000 after acquiring an additional 1,340 shares during the period. Contravisory Investment Management Inc. acquired a new stake in shares of Catalent in the 1st quarter worth about $171,000. Finally, Czech National Bank increased its holdings in shares of Catalent by 0.7% in the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after acquiring an additional 228 shares during the period.

Catalent Stock Performance

Shares of CTLT stock opened at $56.01 on Friday. Catalent has a one year low of $31.45 and a one year high of $60.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The company has a 50 day moving average price of $56.79 and a 200 day moving average price of $48.39. The firm has a market capitalization of $10.14 billion, a price-to-earnings ratio of -8.24, a price-to-earnings-growth ratio of 5.98 and a beta of 1.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company posted $0.62 EPS. The business’s revenue for the quarter was down 10.2% on a year-over-year basis. Sell-side analysts anticipate that Catalent will post 0.28 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.